Bis-(imidazole/benzimidazole)-pyridine derivatives: Synthesis, structure and antimycobacterial activity
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
857 0
SM ISO690:2012
ANTOCI, Vasilichia, CUCU, Dumitrela, ZBANCIOC, Gheorghita N., MOLDOVEANU, Costel, MANGALAGIU, Violeta, AMĂRIUCĂI-MANTU, Dorina, ARICU, Aculina, MANGALAGIU, Ionel. Bis-(imidazole/benzimidazole)-pyridine derivatives: Synthesis, structure and antimycobacterial activity. In: Future Medicinal Chemistry, 2020, nr. 3(12), pp. 207-222. ISSN 1756-8919. DOI: https://doi.org/10.4155/fmc-2019-0063
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Future Medicinal Chemistry
Numărul 3(12) / 2020 / ISSN 1756-8919 /ISSNe 1756-8927

Bis-(imidazole/benzimidazole)-pyridine derivatives: Synthesis, structure and antimycobacterial activity

DOI: https://doi.org/10.4155/fmc-2019-0063

Pag. 207-222

Antoci Vasilichia1, Cucu Dumitrela1, Zbancioc Gheorghita N.1, Moldoveanu Costel1, Mangalagiu Violeta21, Amăriucăi-Mantu Dorina1, Aricu Aculina3, Mangalagiu Ionel1
 
1 Alexandru Ioan Cuza University of Iaşi,
2 Institute of Interdisciplinary Research – CERNESIM Centre,
3 Institute of Chemistry
 
Proiecte:
 
Disponibil în IBN: 6 martie 2020


Rezumat

Aim: Over the last decades, few significant achievements have been made in tuberculosis (TB) therapy. As a result, there is an urgent need for new anti-TB drugs. Results: Two new classes of bis-(imidazole/benzimidazole)-pyridine derivatives were designed, synthesized and evaluated for their antimycobacterial activity. Conclusion: The synthesis is efficient and straightforward, involving only two successive N-alkylations. The anti-TB assay reveal that our compounds have an excellent anti-TB activity against both replicating and nonreplicating Mtb, are not cytotoxic, exhibited a very good intracellular activity and are active against drug-resistant Mtb strains, some compounds have a bactericidal mechanism. The absorption, distribution, metabolism, excretion and toxicity studies performed for one compound are promising, indicating that it is a good candidate for a future drug.

Cuvinte-cheie
ADMET, antimycobacterial, bis-(imidazole/benzimidazole)-pyridine, MBC, MIC

Google Scholar Export

<meta name="citation_title" content="Bis-(imidazole/benzimidazole)-pyridine derivatives: Synthesis, structure and antimycobacterial activity">
<meta name="citation_author" content="Antoci Vasilichia">
<meta name="citation_author" content="Cucu Dumitrela">
<meta name="citation_author" content="Zbancioc Gheorghita N.">
<meta name="citation_author" content="Moldoveanu Costel">
<meta name="citation_author" content="Mangalagiu Violeta">
<meta name="citation_author" content="Amăriucăi-Mantu Dorina">
<meta name="citation_author" content="Aricu Aculina">
<meta name="citation_author" content="Mangalagiu Ionel">
<meta name="citation_publication_date" content="2020/02/27">
<meta name="citation_journal_title" content="Future Medicinal Chemistry">
<meta name="citation_volume" content="12">
<meta name="citation_issue" content="3">
<meta name="citation_firstpage" content="207">
<meta name="citation_lastpage" content="222">
<meta name="citation_pdf_url" content="https://www.future-science.com/doi/10.4155/fmc-2019-0063">